Pressure BioSciences, Inc. and Cannaworx Merger

Apr 29, 2020

Pressure BioSciences, Inc. Announces Plans to Acquire Cannaworx, Inc.

Posted by Pressure BioSciences, Inc.

Merger Combines Cannaworx’s Proprietary Portfolio of Innovative Consumer Products
with the Application of PBI’s Breakthrough Ultra Shear Technology in the
Pain Relief, Cosmeceuticals, Nutraceuticals, Pharmaceuticals, Agriculture, and Veterinary Fields

South Easton, MA, April 29, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the
development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to
the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today
announced that it has signed a binding letter of intent to merge with Cannaworx, Inc. (USA) and its diverse portfolio of
products and intellectual property developed by its founders Bobby Ghalili, DMD and Adrienne Denese, MD, PhD.

Drs. Ghalili & Denese bring extensive medical expertise and product innovation, along with a successful multi-year track record of developing and selling personal care and nutrition products into the newly combined public company. Currently, Cannaworx and its principals have twelve products, including several novel products that utilize the company’s patented/patent pending, full and partial spectrum, hemp-derived phytocannabinoid formulations for pain relief. Cannaworx plans to launch many of these products in 2020, two of which with a pain indication allowed under an FDA OTC monograph, which the company believes will make them the only oral hemp-derived phytocannabinoid-containing products available in today’s market with such a claim. (

Post-merger, Cannaworx products will utilize PBI’s proprietary Ultra Shear Technology™ (UST™) platform. UST is a revolutionary, patented method for processing oil-based products (e.g., hemp-derived CBD oil in water) into long-term stable, highly bioabsorbable, top quality nanoemulsions PBI UST CBD Video 022720. The Company believes UST processing will further increase the bioavailability and efficacy of the Cannaworx human, veterinary, and agricultural products; reduce manufacturing costs; increase profit margins; and distinguish the Cannaworx product lines for quality and performance.

Download Attachment

See all Member News